UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  February 10, 2021

MACROGENICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-36112	06-1591613
(State or Other Jurisdiction of Incorporation)		(Commission File Number)	(IRS Employer  Identification No.)
9704 Medical Center Drive
Rockville,	Maryland	20850
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code:  (301) 251-5172

Not applicable 

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	MGNX	Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Corporate Governance and Management

On February 10, 2021, the Board of Directors (the "Board") of MacroGenics, Inc. (the "Company") approved the appointment of Federica O'Brien to serve as a director on the Board, effective immediately. Ms. O'Brien has been designated a Class I director to hold office until the Company's 2023 Annual Meeting of Stockholders, or until her successor has been duly elected and qualified, or until her earlier resignation or removal. In addition, Ms. O’Brien has been appointed to the Audit Committee of the Board.

Consistent with the Company's Director Compensation Program for non-employee directors, as described under the heading "Director Compensation" in the Company's most recent proxy statement filed with the Securities and Exchange Commission on April 3, 2020, Ms. O'Brien will receive an annual retainer of $40,000, which will be prorated from the date of her appointment to the Board. In addition, upon appointment to the Board, Ms. O'Brien has been granted an option to purchase 30,000 shares of the Company's common stock at an exercise price of $21.50 per share, the closing market price of the Company's common stock on the date of grant, and vesting in 12 substantially equal monthly portions beginning on the first monthly anniversary of the date of grant, subject to Ms. O'Brien's continued service on the Board through each vesting date.

There are no arrangements or understandings between Ms. O'Brien and any other person pursuant to which Ms. O'Brien was selected as a director, and there are no transactions in which the Company is a party and in which Ms. O'Brien has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

A copy of the press release announcing the appointment of Ms. O'Brien to the Board is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01	Financial Statements and Exhibits
(d) Exhibits.
Exhibit Number	Description of Exhibit
99.1	Press Release, dated February 11, 2021.
104	Cover Page Interactive Data (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MACROGENICS, INC.
Date: February 11, 2021	By: Name: Title:	/s/ Jeffrey Peters Jeffrey Peters Vice President and General Counsel